Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting

Kalshetty, A.Ramaswamy, A.Ostwal, V.Basu, Sandip2019-06-032019-06-032018Nuclear Medicine Communications, 2018. Vol. 39 (12): pp. 1143-1149http://hdl.handle.net/123456789/186225177 bytestext/htmlenfunctioning gastroenteropancreatic neuroendocrine tumors68Ga-DOTATATE177Lu-DOTATATEneuroendocrine tumorpeptide receptor radionuclide therapyResistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this settingArticle